Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees

Journal of Virology

Volumn 74, Issue 17, 2000, Pages 7699-7707

  Beaumont, T ^a   Broersen, S ^a   Van Nuenen, A ^a   Huisman, H G ^a   De Roda Husman, A M ^a   Heeney, J L ^a   Schuitemaker, H ^a  

^a CENTRAL LABORATORY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; IMMUNOGLOBULIN G; IODINE 125;

ANTIGEN RECOGNITION; ARTICLE; BINDING SITE; CELL SURFACE; CHIMPANZEE; DISEASE COURSE; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOTOPE LABELING; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS REPLICATION;

ANIMALS; ANTIBODIES; ANTIGENS, CD4; CELLS, CULTURED; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; NEUTRALIZATION TESTS; PAN TROGLODYTES; PHENOTYPE; RECEPTORS, CCR5; RECEPTORS, CXCR4; TIME FACTORS; VIRUS REPLICATION;

EID: 0033894973     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.17.7699-7707.2000     Document Type: Article

References (68)

1. Transmission of HTLV-III infection from human plasma to chimpanzees: An animal model for AIDS
2. Conserved CTL epitopes shared between HIV-infected human long-term survivors and chimpanzees
3. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160
4. Characteristics of primary infection of a European human immunodeficiency virus type 1 clade B isolate in chimpanzee
5. Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors
6. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzee
7. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody
8. A CD4 domain important for HIV-mediated syncytium formation lies outside the virus binding site
9. Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiple passaged simian-human immunodeficiency virus (SHIV-HXBc2)
10. A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects
11. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
12. Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression
13. Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors
14. + T cells in human immunodeficiency virus type 1-infected chimpanzees is associated with increased lymphocyte apoptosis
15. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody
16. An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies
17. Persistent infection of chimpanzees with human T-lymphotropic virus type III/lymphadenopathy associated virus: A potential model for acquired immunodeficiency syndrome
18. The inability of human immunodeficiency virus to infect chimpanzee monocytes can be overcome by serial viral passage in vivo
19. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus
20. Apoptosis in AIDS
21. Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection
22. Immune strategies utilized by lentivirus infected chimpanzees to resist progression to AIDS
23. The resistance of HIV-infected chimpanzees to progression to AIDS correlates with absence of HIV-related T-cell dysfunction
24. AIDS: A disease of impaired Th-cell renewal?
25. Immune correlates of protection from HIV infection and AIDS
26. Recognition properties of V3-specific antibodies to V3-loop peptides derived from HIV-1 gp120 presented in multiple conformations
27. Detection of early anti-p24 HIV responses in EIA- and immunoblot-negative individuals. Implications for confirmatory testing
28. Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression
29. + cytotoxic lymphocytes
30. + cell depletion and progression to AIDS
31. CD4, CXCR-4, and CCR5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1
32. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
33. Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity
34. Fusion-competent vaccines: Broad neutralization of primary isolates of HIV
35. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain
36. Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants
37. Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection
38. HIV infection of primate lymphocytes and conservation of the CD4 receptor
39. Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12
40. Evidence that antibody mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage
41. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals
42. HIV-1 neutralization: The consequences of viral adaptation to growth on transformed T cells
43. Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4
44. The biology of human immunodeficiency virus-1 IIIB infection in the chimpanzee: In vivo and in vitro correlations
45. Persistent infection of chimpanzees with human immunodeficiency virus: Serological responses and properties of reisolated viruses
46. Emergence of virus resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees
47. Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1
48. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection
49. Infectious properties of human immunodeficiency virus type 1 mutants with distinct affinities for the CD4 receptor
50. Chimpanzee CXCR4 and CCR5 act as coreceptors for HIV type 1
51. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding
52. Virus-specific cytotoxic T lymphocytes in human immunodeficiency virus type 1-infected chimpanzees
53. Molecular cloning and characterization of a German HIV-1 isolate
54. Interplay of HIV-1 phenotype and neutralizing antibody response in pathogenesis of AIDS
55. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine mediated suppression
56. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations
57. Lack of T-cell dysfunction and programmed cell death in human immunodeficiency virus type-1 infected chimpanzees correlates with absence of monocytotropic variants
58. Further characterization of an antigenic site of HIV-1 gp120 recognized by virus neutralizing human monoclonal antibodies
59. Isolation and characterization of a syncytium-inducing, macrophage/T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo
60. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates
61. Intact CCR-5 coreceptors in HIV-1 infected chimpanzees
62. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage
63. Evolution of syncytium inducing and non-syncytium inducing biological virus clones in relation to replication kinetics during the course of HIV-1 infection
64. A chimpanzee-passaged human immunodeficiency virus isolate is cytopathic for chimpanzee cells but does not induce disease
65. Risk of human immunodeficiency virus (HIV-1) infection among laboratory workers
66. The antigenic structure of the HIV gp120 envelope protein
67. Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection
68. Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors